These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2526172)

  • 1. The new selective D2-dopamine receptor antagonist raclopride--pharmacokinetics, safety and tolerability in healthy males.
    Farde L; von Bahr C; Wahlen A; Nilsson L; Widman M
    Int Clin Psychopharmacol; 1989 Apr; 4(2):115-26. PubMed ID: 2526172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.
    Farde L; Wiesel FA; Jansson P; Uppfeldt G; Wahlen A; Sedvall G
    Psychopharmacology (Berl); 1988; 94(1):1-7. PubMed ID: 3126517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
    Nordström AL; Farde L
    J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
    Seeman P; Tallerico T
    Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers.
    Movin-Osswald G; Nordström AL; Hammarlund-Udenaes M; Wahlén A; Farde L
    Clin Pharmacokinet; 1992 Feb; 22(2):152-61. PubMed ID: 1551292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.
    Bench CJ; Lammertsma AA; Dolan RJ; Grasby PM; Warrington SJ; Gunn K; Cuddigan M; Turton DJ; Osman S; Frackowiak RS
    Psychopharmacology (Berl); 1993; 112(2-3):308-14. PubMed ID: 7871035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.
    Farde L
    Psychopharmacology (Berl); 1992; 107(1):23-9. PubMed ID: 1534178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and tolerability of raclopride, a specific D2 receptor blocker, in acute schizophrenia: an open trial.
    Cookson JC; Natorf B; Hunt N; Silverstone T; Uppfeldt G
    Int Clin Psychopharmacol; 1989 Jan; 4(1):61-70. PubMed ID: 2531773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
    Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of specific dopamine D1 and D2 receptor antagonists and agonists and neuroleptic drugs on emotional defecation in a rat model of akathisia.
    Sachdev PS; Saharov T
    Psychiatry Res; 1998 Dec; 81(3):323-32. PubMed ID: 9925183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.
    Farde L; Halldin C; Stone-Elander S; Sedvall G
    Psychopharmacology (Berl); 1987; 92(3):278-84. PubMed ID: 2957716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.
    Wiesel FA; Nordström AL; Farde L; Eriksson B
    Psychopharmacology (Berl); 1994 Feb; 114(1):31-8. PubMed ID: 7846205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients.
    McEvoy JP; Movin-Osswald G; Uppfeldt G; Williams T; Dutcher S; Apperson J
    Psychopharmacology (Berl); 1993; 112(2-3):371-4. PubMed ID: 7871044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy--a simulation study based on experimental data.
    Olsson H; Farde L
    Neuroimage; 2001 Oct; 14(4):936-45. PubMed ID: 11554812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
    Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE
    Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of rate of administration of raclopride on akathisia and prolactin response.
    Movin-Osswald G; Karlsson P; Hammarlund-Udenaes M; Farde L
    Psychopharmacology (Berl); 1994 Mar; 114(2):248-56. PubMed ID: 7838916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.